Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Raw Materials (2022 - 2026)

Gyre Therapeutics has reported Raw Materials over the past 4 years, most recently at $970000.0 for Q4 2025.

  • Quarterly Raw Materials rose 22.17% to $970000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $970000.0 through Dec 2025, up 22.17% year-over-year, with the annual reading at $970000.0 for FY2025, 22.17% up from the prior year.
  • Raw Materials was $970000.0 for Q4 2025 at Gyre Therapeutics, down from $1.1 million in the prior quarter.
  • Over five years, Raw Materials peaked at $1.2 million in Q2 2025 and troughed at $724000.0 in Q1 2024.
  • The 4-year median for Raw Materials is $1.0 million (2022), against an average of $1.0 million.
  • Year-over-year, Raw Materials fell 13.6% in 2024 and then skyrocketed 61.46% in 2025.
  • A 4-year view of Raw Materials shows it stood at $1.1 million in 2022, then dropped by 12.97% to $919000.0 in 2023, then dropped by 13.6% to $794000.0 in 2024, then grew by 22.17% to $970000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Raw Materials are $970000.0 (Q4 2025), $1.1 million (Q3 2025), and $1.2 million (Q2 2025).